Compare MRT & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRT | SGMT |
|---|---|---|
| Founded | 2018 | 2006 |
| Country | Turkey | United States |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.0M | 169.4M |
| IPO Year | 2021 | 2021 |
| Metric | MRT | SGMT |
|---|---|---|
| Price | $1.43 | $7.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $3.58 | ★ $26.13 |
| AVG Volume (30 Days) | 55.6K | ★ 1.2M |
| Earning Date | 08-08-2018 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | $72.36 | N/A |
| Revenue Next Year | $95.75 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.12 | $4.50 |
| 52 Week High | $3.11 | $11.41 |
| Indicator | MRT | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 33.34 | 58.68 |
| Support Level | N/A | $7.09 |
| Resistance Level | $2.26 | $8.80 |
| Average True Range (ATR) | 0.13 | 0.39 |
| MACD | -0.03 | 0.10 |
| Stochastic Oscillator | 41.16 | 71.05 |
Marti Technologies Inc is Turkiye's urban mobility platform, helping to solve the country's transportation needs through tech-enabled services powered by a single mobility super app. The Group aims to offer tech-enabled urban transportation services to consumers across Turkiye through three service offerings: ride-hailing, delivery, and two-wheeled electric vehicle services. The Group's ride-hailing service matches consumers with car, motorcycle, and taxi drivers. The Group's delivery service provides same-hour package delivery by leveraging the Group's existing network of car and motorcycle drivers and consumer base.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.